JP2013503202A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503202A5
JP2013503202A5 JP2012527071A JP2012527071A JP2013503202A5 JP 2013503202 A5 JP2013503202 A5 JP 2013503202A5 JP 2012527071 A JP2012527071 A JP 2012527071A JP 2012527071 A JP2012527071 A JP 2012527071A JP 2013503202 A5 JP2013503202 A5 JP 2013503202A5
Authority
JP
Japan
Prior art keywords
formulation
sdf
administered
use according
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012527071A
Other languages
English (en)
Japanese (ja)
Other versions
JP5856059B2 (ja
JP2013503202A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/047175 external-priority patent/WO2011026041A2/en
Publication of JP2013503202A publication Critical patent/JP2013503202A/ja
Publication of JP2013503202A5 publication Critical patent/JP2013503202A5/ja
Application granted granted Critical
Publication of JP5856059B2 publication Critical patent/JP5856059B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012527071A 2009-08-28 2010-08-30 虚血組織を治療するためのsdf−1送達 Active JP5856059B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23777509P 2009-08-28 2009-08-28
US61/237,775 2009-08-28
US33421610P 2010-05-13 2010-05-13
US61/334,216 2010-05-13
PCT/US2010/047175 WO2011026041A2 (en) 2009-08-28 2010-08-30 Sdf-1 delivery for treating ischemic tissue

Publications (3)

Publication Number Publication Date
JP2013503202A JP2013503202A (ja) 2013-01-31
JP2013503202A5 true JP2013503202A5 (enExample) 2013-10-10
JP5856059B2 JP5856059B2 (ja) 2016-02-09

Family

ID=43628693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012527071A Active JP5856059B2 (ja) 2009-08-28 2010-08-30 虚血組織を治療するためのsdf−1送達

Country Status (9)

Country Link
US (5) US20120283315A1 (enExample)
EP (1) EP2473196B1 (enExample)
JP (1) JP5856059B2 (enExample)
CN (1) CN102740894B (enExample)
AU (1) AU2010286511B2 (enExample)
BR (1) BR112012004395B8 (enExample)
CA (1) CA2772610C (enExample)
MX (1) MX357779B (enExample)
WO (1) WO2011026041A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
ES2520044T3 (es) 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
AU2008338525B2 (en) 2007-12-14 2015-04-02 Juventas Therapeutics, Inc. Compositions and methods of promoting wound healing
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US20130295064A1 (en) * 2010-10-14 2013-11-07 University Of Central Florida Research Foundation, Inc. Cardiac induced pluripotent stem cells and methods of use in repair and regeneration of myocardium
US20130136729A1 (en) * 2011-11-11 2013-05-30 University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors
WO2014145199A2 (en) * 2013-03-15 2014-09-18 The Cleveland Clinic Foundation Retrograde delivery of sdf-1 for treatment of myocardial infarction
KR20160005021A (ko) * 2013-03-15 2016-01-13 더 클리브랜드 클리닉 파운데이션 허혈 조직 처리를 위한 sdf-1의 전달
AU2014233266A1 (en) * 2013-03-15 2015-10-22 Juventas Therapeutics, Inc. The use of SDF-1 to mitigate scar formation
US20160278810A1 (en) 2013-05-31 2016-09-29 Mark Edmund Richey Vaginal surgical apparatus
US10166044B1 (en) 2013-05-31 2019-01-01 Freshwater Bay Industries, Llc Apparatus for repositioning the vagina, cervix, uterus and pelvic floor and method to secure same
WO2015168145A1 (en) * 2014-04-28 2015-11-05 Penn Marc S Sdf-1 delivery for treating advanced ischemic cardiomyopathy
EP3139945B1 (en) 2014-05-08 2025-08-27 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
EP3237622B1 (en) 2014-12-23 2021-02-24 Ilya Pharma AB Methods for wound healing
WO2017083750A1 (en) 2015-11-11 2017-05-18 Intrexon Corporation Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
WO2018183625A1 (en) * 2017-03-30 2018-10-04 Wake Forest University Health Sciences Methods of treatment for kidney disease
WO2018213125A1 (en) 2017-05-13 2018-11-22 The Johns Hopkins University Stromal derived factor 1 and it's use in the prevention and treatment of erectile dysfunction
US11654181B2 (en) 2017-08-11 2023-05-23 Wake Forest University Health Sciences Use of CXCL12 for therapy after prostate surgery
EP3781182A4 (en) * 2018-04-18 2021-11-17 Summa Health COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA
EP4473544A1 (en) * 2022-02-04 2024-12-11 Elixirgen Therapeutics, Inc. Cell therapy protocol systems and methods

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US20020031803A1 (en) * 1997-06-20 2002-03-14 Cooper Mark J. Expression system for production of therapeutic proteins
US5602301A (en) 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
US6100242A (en) 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US6121246A (en) 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
BR9806819A (pt) * 1997-01-29 2000-05-09 Cornell Res Foundation Inc Fornecimento de múltiplos locais de vetor adenoviral para a indução de angiogênese.
US6121428A (en) 1997-06-13 2000-09-19 Genentech, Inc. Protein recovery
MXPA00003885A (es) 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
CN1295617A (zh) 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子-血管内皮细胞生长因子vegf的突变体
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
WO1999045775A1 (en) 1998-03-09 1999-09-16 St. Elizabeth's Medical Center Compositions and methods for modulating vascularization
EP2308996A1 (en) 1998-03-30 2011-04-13 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis
US20020107195A1 (en) 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
IL125532A0 (en) 1998-07-27 1999-03-12 Yeda Res & Dev Hematopoietic cell composition for use in transplantation
AU5241099A (en) 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
EP1113836A4 (en) * 1998-09-14 2008-01-23 Mirus Bio Corp METHOD FOR DELIVERY OF NUCLEIC ACIDS TO CARDIAC TISSUES
DE19844479C1 (de) 1998-09-28 2000-04-13 Siemens Ag Integrierter Speicher mit einem differentiellen Leseverstärker
US7399751B2 (en) 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
EP1013770A1 (en) * 1998-12-23 2000-06-28 Université Louis Pasteur de Strasbourg Non-viral transfection vector
DE19900743A1 (de) * 1999-01-12 2000-07-13 Aventis Pharma Gmbh Neue komplexbildende Proteine
US6333194B1 (en) 1999-01-19 2001-12-25 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
EP1154780A2 (en) 1999-02-26 2001-11-21 University Of Pittsburgh Of The Commonwealth System Of Higher Education Bone marrow transplantation for hepatic regeneration and repair
US20050153451A1 (en) * 1999-02-26 2005-07-14 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
EP1041148A1 (en) 1999-04-02 2000-10-04 Mogen International N.V. Pathogen inducible promoter
WO2000059941A1 (en) 1999-04-08 2000-10-12 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
US7125856B1 (en) 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
AU4801501A (en) * 2000-05-26 2001-11-29 Transgene S.A. Complex for transferring an anionic substance of interest into a cell
EP2324839B1 (en) 2000-06-05 2017-08-09 The Trustees of Columbia University in the City of New York Granulocyte-colony-stimulating-factor (g-csf) for use in the treatment of myocardial infarct
WO2002009650A2 (en) 2000-07-31 2002-02-07 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
KR20020059609A (ko) * 2000-08-04 2002-07-13 벤슨 로버트 에이치. 혈관 내피 성장 인자 2
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
US7402567B2 (en) 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US20020094327A1 (en) 2000-11-05 2002-07-18 Petersen Bryon E. Targeting pluripotent stem cells to tissues
AU2002224851A1 (en) 2000-11-14 2002-05-27 Universite Libre De Bruxelles Generation and use of dendritic cells
US20020111290A1 (en) 2000-12-01 2002-08-15 Bernhard Homey Uses of mammalian genes and related reagents
AR027161A1 (es) * 2001-05-15 2003-03-19 Bio Sidus S A Metodo para inducir la proliferacion neovascular y regeneracion tisular
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
EP1424389A4 (en) 2001-08-07 2004-08-25 Kirin Brewery METHOD FOR PRODUCING HEMATOPOETIC STEM CELLS
EP1430114B1 (en) 2001-09-14 2012-01-18 Stem Cell Therapeutics Inc. Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
US7402724B2 (en) 2002-01-04 2008-07-22 Mayo Foundation For Medical Education And Research Longevity and PAPP-A
WO2003059375A1 (en) 2002-01-17 2003-07-24 Cardio Incorporated Complex therapy for tissue regeneration
FR2843697B1 (fr) * 2002-08-26 2005-12-09 Sod Conseils Rech Applic L'heterocarpine, une proteine d'origine vegetale aux proprietes anticancereuses
US7396537B1 (en) 2002-02-28 2008-07-08 The Trustees Of The University Of Pennsylvania Cell delivery patch for myocardial tissue engineering
US7282222B2 (en) 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US20040161412A1 (en) * 2002-08-22 2004-08-19 The Cleveland Clinic Foundation Cell-based VEGF delivery
JP2004099471A (ja) 2002-09-05 2004-04-02 Cardio Corp 心筋梗塞および心不全の治療薬
WO2004033396A2 (en) 2002-10-08 2004-04-22 American National Red Cross Method for enriching adherent monocyte populations
WO2004044142A2 (en) 2002-11-05 2004-05-27 The Brigham And Women's Hospital, Inc. Mesenchymal stem cells and methods of use thereof
US20040258670A1 (en) 2002-12-05 2004-12-23 Case Western Reserve University Cell-based therapies for ischemia
KR20050111593A (ko) * 2003-02-19 2005-11-25 가부시키가이샤 디나벡크 겐큐쇼 허혈질환의 치료방법
AU2003902037A0 (en) 2003-04-24 2003-05-15 Mclachlan, Craig Method for tissue growth
US20050104072A1 (en) 2003-08-14 2005-05-19 Slater David B.Jr. Localized annealing of metal-silicon carbide ohmic contacts and devices so formed
US7396680B2 (en) 2003-10-31 2008-07-08 Cornell Research Foundation, Inc. Stem cell-specific promoters and their use
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
US8071364B2 (en) * 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
AU2005258052B2 (en) 2004-06-21 2008-11-27 The Cleveland Clinic Foundation CCR ligands for stem cell homing
WO2006030887A1 (ja) 2004-09-17 2006-03-23 Cellgentech, Inc. 外用皮膚潰瘍治療剤
WO2006037031A2 (en) * 2004-09-27 2006-04-06 Valentis, Inc. Formulations and methods for treatment of inflammatory diseases
US20060105950A1 (en) 2004-10-25 2006-05-18 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Morphogen compositions and use thereof to treat wounds
WO2006083394A2 (en) 2004-12-21 2006-08-10 Ethicon, Inc. Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US7951632B1 (en) 2005-01-26 2011-05-31 University Of Central Florida Optical device and method of making
GB2424312B (en) 2005-03-14 2010-03-03 Denso Corp Method of forming an ohmic contact in wide band semiconductor
KR20080046658A (ko) 2005-09-16 2008-05-27 크리 인코포레이티드 실리콘 카바이드 전력 소자들을 그 상에 가지는 반도체웨이퍼들의 가공방법들
US8664664B2 (en) 2006-01-10 2014-03-04 Cree, Inc. Silicon carbide dimpled substrate
US20070173471A1 (en) 2006-01-24 2007-07-26 Losordo Douglas W Morphogen compositions and methods of use thereof to treat heart disorders
US7405195B2 (en) 2006-03-27 2008-07-29 Natural Beauty Bio-Technology Limited Cosmetic compositions
ES2520044T3 (es) 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
AU2008338525B2 (en) 2007-12-14 2015-04-02 Juventas Therapeutics, Inc. Compositions and methods of promoting wound healing
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
US20130252876A1 (en) 2010-09-15 2013-09-26 The Cleveland Clinic Foundation Compositions and method for promoting musculoskeletal repair
US20120068161A1 (en) 2010-09-16 2012-03-22 Lee Keon-Jae Method for forming graphene using laser beam, graphene semiconductor manufactured by the same, and graphene transistor having graphene semiconductor
JP5569376B2 (ja) 2010-12-07 2014-08-13 住友電気工業株式会社 半導体装置の製造方法

Similar Documents

Publication Publication Date Title
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
JP2022537570A (ja) がんを処置する方法
JP2018531984A5 (enExample)
JP2014516702A5 (enExample)
JP2014526441A5 (enExample)
JP2008507536A5 (enExample)
FI3484446T3 (fi) Vasta-ainekoostumuksia
JP2015518818A5 (enExample)
MX2022007012A (es) Uso de un agonista doble del receptor de glp-1/glucagon de larga accion para el tratamiento de la enfermedad de higado graso no alcoholico.
PE20091583A1 (es) Solucion para infusion de dihidropteridinonas estabilizada para el almacenamiento
JP2012516856A5 (enExample)
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
JP2014501762A5 (enExample)
JP2012515221A5 (enExample)
RU2020109881A (ru) Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита
JP2017523985A5 (enExample)
JP2020517601A5 (enExample)
JP2019512543A5 (enExample)
JP2010524968A5 (enExample)
JP2016530284A5 (enExample)
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
JP2023520004A5 (enExample)
JP2014510782A5 (enExample)
IL275273B2 (en) Improved compound for treatment of heart failure
JP2011504736A5 (enExample)